Printer Friendly

Ciphergen Biosystems announces issuance of European Patent covering a method for aiding bladder cancer diagnosis.

Ciphergen Biosystems, Inc. (Fremont, CA) announced that the European Patent Office has issued EU Patent 1 354 203, entitled "Biomarkers of Transitional Cell Carcinoma of the Bladder," for aiding in bladder cancer diagnosis when used in conjunction with the current standard of care -- cystoscopy (a diagnostic procedure that uses a scope to view the bladder). The patent describes using mass spectrometry to detect certain protein biomarkers that are present in patients with bladder cancer versus patients who do not have bladder cancer. These discoveries were made under a collaborative agreement between Ciphergen and Eastern Virginia Medical School. Ciphergen retains exclusive rights to these discoveries for diagnostic development.

"The issuance of this patent is another example of Ciphergen's growing intellectual property portfolio and the productivity of our collaborations, which continue to support the expansion of our high-value diagnostic development programs," said Gail S. Page, Chief Executive Officer of Ciphergen Biosystems. "In collaboration with our partners, we continue to generate promising biomarker data that may be useful for aiding physicians in cancer diagnosis, disease monitoring, or prediction of recurrence."

The American Cancer Society estimates approximately 67,000 new cases of bladder cancer diagnosed in the United States (about 50,040 men and 17,120 women) in 2007. An estimated 13,750 deaths from bladder cancer will occur this year in the United States (about 9,630 men and 4,120 women).

Ciphergen is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer.

Ciphergen Biosystems, Inc.

+1-510-505-2233

www.ciphergen.com
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:May 1, 2007
Words:285
Previous Article:Novacea and Schering-Plough enter into worldwide development and commercialization agreement for Asentar.
Next Article:Neuralstem's cells restore motor function in spinal ischemia-paralyzed rats.
Topics:


Related Articles
Matritech issued patent extending coverage of its NMP22 test kit for bladder cancer until 2015.
Ciphergen announces protein expression profiling patent issuance.
2003 litigation update.
Ciphergen announces issuance of patent for SELDI-TOF-MS assisted protein purification complements existing patents covering Ciphergen's biomarker...
DiagnoCure granted patent for PCA3.
Ciphergen receives notice of intent from United States Patent and Trademark Office for re-Issuance of SELDI mass spectrometry patent.
Ciphergen licenses more than 25 patents from Health Discovery.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters